What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino acid sequence derived from a protective protein found in human gastric juice. Its amino acid sequence is GEPPPGKPADDAGLV, with a molecular weight of 1419.53 g/mol. Unlike many research peptides that are synthetic analogues of human hormones, BPC-157’s parent protein is naturally produced in the gastrointestinal tract, where it plays a role in mucosal integrity and tissue protection.
BPC-157 has been studied extensively in preclinical models for its effects on angiogenesis, wound healing, inflammation, and tissue repair across multiple organ systems. For a comprehensive overview of BPC-157’s mechanisms and research findings, see our BPC-157 Complete Research Guide.
BPC-157 Dosage in Published Research
BPC-157 dosage data comes exclusively from animal studies and in vitro experiments — no human clinical trials have been completed or published in peer-reviewed journals as of 2026. This is an important distinction: all dosage information discussed below is derived from preclinical research, and translation to human equivalents involves significant uncertainty.
Animal study dosages
The majority of published BPC-157 research uses rodent models (rats and mice). Dosages across the literature generally fall within the following ranges:
| Administration Route | Typical Dose Range | Most Common Dose | Frequency |
|---|---|---|---|
| Intraperitoneal (IP) | 10-50 mcg/kg | 10 mcg/kg | Once daily |
| Subcutaneous (SC) | 10-50 mcg/kg | 10 mcg/kg | Once daily |
| Oral (in drinking water) | 10 mcg/kg – 10 ng/kg | 10 mcg/kg | Continuous access |
| Topical (cream) | 1-10 mcg/cm² | Variable | Once or twice daily |
A notable finding across BPC-157 research is the compound’s effectiveness at both microgram (mcg/kg) and nanogram (ng/kg) doses — a 1,000-fold range. This unusually wide effective dose range has been observed in multiple independent studies across different tissue types and injury models, suggesting a mechanism that does not follow simple linear dose-response kinetics.
Calculating human equivalent doses (HED)
The FDA-recommended method for converting animal doses to human equivalent doses uses body surface area (BSA) normalization rather than simple weight-based scaling. For rats, the conversion factor is approximately 6.2 — meaning a rat dose in mg/kg is divided by 6.2 to estimate the human equivalent dose in mg/kg.
| Rat Dose (mcg/kg) | HED (mcg/kg) | HED for 80kg human |
|---|---|---|
| 10 mcg/kg (low end) | 1.6 mcg/kg | ~128 mcg |
| 50 mcg/kg (high end) | 8.1 mcg/kg | ~648 mcg |
These calculations produce estimated human equivalent doses in the range of approximately 100-700 mcg per day. Within the research community, the most commonly discussed doses fall between 200-500 mcg administered once or twice daily via subcutaneous injection.
Dosage by Research Application
Published preclinical studies have investigated BPC-157 across a wide range of tissue types and injury models. The dosing protocols vary by application:
Musculoskeletal and tendon repair
Rodent studies on tendon healing (Achilles tendon transection models) used 10 mcg/kg IP or SC daily, with treatment durations of 14-28 days. Significant improvements in tendon healing, collagen fiber organization, and biomechanical strength were observed. Similar protocols showed accelerated healing in muscle crush injuries, ligament damage, and bone fracture models.
Gastrointestinal protection
Studies on gastric ulcers, inflammatory bowel disease models, and intestinal anastomosis healing typically used 10 mcg/kg IP or oral administration. BPC-157 demonstrated oral stability — an unusual property for a peptide — and showed efficacy when administered in drinking water, suggesting it can survive the gastric environment in bioactive form. For more on BPC-157’s gut health applications, see our Peptides for Gut Health Research Guide.
Wound healing and skin repair
Topical and systemic BPC-157 administration in burn and wound models used 10-50 mcg/kg. A topical BPC-157 cream formulation outperformed silver sulfadiazine (standard burn treatment) in mouse burn studies. For skin-specific peptide research, see our Best Peptides for Skin Research.
Combined with TB-500 (Wolverine Stack)
BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4) in tissue repair research. BPC-157 promotes angiogenesis and growth factor signaling while TB-500 facilitates actin regulation and cell migration — complementary mechanisms that address different phases of tissue healing. For details on this combination, see our Wolverine Stack: BPC-157 + TB-500 Guide.
Administration Routes
Subcutaneous injection
The most common administration route in research settings. BPC-157 is reconstituted with bacteriostatic water and injected subcutaneously, typically near the area of interest (e.g., near an injured tendon or joint) or in the abdominal area for systemic effects.
Oral administration
BPC-157 demonstrates unusual oral stability for a peptide. Multiple studies have shown efficacy when administered orally in drinking water, with some researchers reporting comparable results to injection routes for gastrointestinal and certain systemic applications. This oral stability is attributed to BPC-157’s origin as a gastric peptide — it evolved to function in the acidic gastric environment.
Reconstitution for Research Use
PSPeptides BPC-157 is supplied as a lyophilized powder. Reconstitute with Hospira bacteriostatic water before use.
For step-by-step reconstitution instructions, see our How to Reconstitute Peptides Guide. Use our free Peptide Reconstitution Calculator to determine exact volumes for your desired concentration.
Duration of Use in Research
Published animal studies range in duration from single-dose acute studies to chronic protocols lasting 30+ days. The most common treatment durations in healing-focused research are:
- Acute injury models: 7-14 days
- Tendon/ligament repair: 14-28 days
- Chronic conditions (GI, inflammation): 28-42 days
- Preventive/protective studies: Duration varies by protocol
No published data establishes maximum safe duration of use. Long-term studies in rats (administered for several months) have not reported significant adverse effects, but these are animal models and may not translate directly.
Safety Observations
Across the published preclinical literature, BPC-157 has demonstrated a remarkably clean safety profile. No organ toxicity, mutagenicity, or significant adverse effects have been reported in animal studies, even at doses substantially above the typical effective range. LD50 (lethal dose) testing has not identified a lethal dose — the compound appears to have an extremely wide therapeutic margin.
However, the absence of human clinical trials means the safety profile in humans remains uncharacterized. For a broader discussion of peptide safety considerations, see our Peptide Side Effects Guide.
Frequently Asked Questions
What is the standard BPC-157 research dose?
The most commonly cited dose in animal research is 10 mcg/kg body weight administered once daily via subcutaneous injection. Using FDA body surface area conversion, this translates to approximately 100-200 mcg per day as a human equivalent estimate.
Can BPC-157 be taken orally?
Unlike most peptides, BPC-157 has demonstrated oral stability and efficacy in multiple animal studies. It originates from gastric juice and appears to retain bioactivity when exposed to stomach acid. Oral and injectable routes have shown comparable results in some GI-related studies.
How long does BPC-157 take to work in research models?
In animal studies, measurable healing improvements are typically observed within 3-7 days, with more substantial structural and functional recovery occurring over 14-28 days. Timeframes vary by tissue type and injury severity.
Should BPC-157 be injected locally or systemically?
Published research has shown efficacy with both local (near the injury site) and systemic (abdominal subcutaneous) injection. Some researchers prefer local injection for musculoskeletal applications and systemic injection for gastrointestinal or multi-site protocols.
References
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865.
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972-1989.
- Chang CH, et al. BPC-157 Promotes Muscle Regeneration. J Orthopaedic Research. 2021;39(12):2628-2637.
- Cesarec V, et al. Pentadecapeptide BPC 157 and the esophagus. Eur J Pharmacol. 2013;701(1-3):150-155.
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.
Buy Research-Grade BPC-157 → | Buy BAC Water → | Buy Syringes →
This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.